マーケットレポート詳細
ワクチンの世界市場：疾患別、技術別2028年予測
Vaccines Market by Technology (Recombinant, Toxoid, Conjugate, RNA), Type (Monovalent, Multivalent), Disease (Pneumococcal, Influenza, DTP, HPV, MMR, COVID-19), Route of Administration (IM, SC, Oral), End user (Pediatric, Adult) & Region - Global Forecast to 2028
- 出版元：MarketsandMarkets
出版元について - 発行年：2023年11月
- 定価 ：Single User License(1名様ライセンス)US$4,950(米国ドル)/ Multi User License(5名様)$6,650 / Corporate User License $8,150
- ご予算に応じた各種ご提案も承ります。詳細はお問い合わせください。
- ご請求は円換算（お見積り日TTSレート）となります。
- 納品形態：PDF by Email
- 当調査レポートは英文371ページになります。
- 商品コード：MAM3461
お問い合わせ、お見積りのリクエストは下のボタンをクリックしてご入力ください。
【レポート紹介】
ワクチンの世界市場規模は2023年の776億ドルから、2028年までに938億ドルへと拡大し、予測期間の市場の平均年成長率は3.9%で推移することが見込まれています。
レポートはワクチンの世界市場について2028年までの市場予測データ(金額US$)を掲載しています。同市場をさまざまな区分で細分化し、そのセグメント市場ごとの市場予測（技術別市場、タイプ別市場、等）を中心に構成されています。また競合状況、主要企業情報（17社）、市場ダイナミクス、価格分析などの分析も加味し、ワクチン市場の動向および今後成長性を詳細にレポートしています。
【レポート構成概要】
◆ワクチンの世界市場予測2021-2028年
・市場規模(US$)
◆技術別、市場-2028年
・結合型ワクチン
・組換えワクチン
・不活化/サブユニットワクチン
・弱毒化生ワクチン
・トキソイドワクチン
・ウイルスベクターワクチン
・mRNAワクチン
・その他ワクチン
※(市場規模US$)
◆タイプ別、市場-2028年
・1価ワクチン
・多価ワクチン
※(市場規模US$)
◆疾患別、市場-2028年
・肺炎球菌疾患
・インフルエンザ
・混合ワクチン
・HPV
・髄膜炎菌性疾患
・帯状疱疹
・ロタウイルス
・MMR
・水痘
・肝炎
・DTP
・ポリオ
・その他疾患
※(市場規模US$)
◆投与経路別、市場-2028年
・筋内/皮下投与
・経口投与
・その他投与経路
※(市場規模US$)
◆エンドユーザー別、市場-2028年
・小児用ワクチン
・成人用ワクチン
※(市場規模US$)
◆主要国地域別市場-2028年
北米
・米国、カナダ
欧州
・ドイツ、英国、フランス、イタリア、スペイン
・その他欧州
アジア太平洋
・日本、韓国、中国、インド
・その他アジア太平洋
中南米
・ブラジル、メキシコ
・その他中南米
中東アフリカ
・中東
・アフリカ
※国地域別に全セグメント別の細分化データ掲載、詳細は目次参照
◆市場分析
・市場ダイナミクス（促進要因、障壁、機会、課題）
・価格分析
・バリューチェーン分析
・パイプライン分析
・エコシステム市場/マップ
・規制分析
・業界構造分析（ファイブフォース分析）
・特許分析
・競合状況
・市場シェア分析
◆ワクチンの主要企業プロフィール動向
・PFIZER INC.
・MERCK & CO., INC.
・GSK PLC
・SANOFI
・CSL
・EMERGENT
・JOHNSON & JOHNSON SERVICES, INC.
・ASTRAZENECA
・SERUM INSTITUTE OF INDIA PVT., LTD.
・BAVARIAN NORDIC
・田辺三菱製薬株式会社
・第一三共株式会社
・PANACEA BIOTEC
・BIOLOGICAL E LIMITED
・BHARAT BIOTECH
・NOVAVAX
・INOVIO PHARMACEUTICALS
（その他企業）
・SINOVAC
・INCEPTA PHARMACEUTICALS LTD.
・VALNEVA SE
・VBI VACCINES INC.
・BIO FARMA
・FSUE NPO MICROGEN
・ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.
・INDIAN IMMUNOLOGICALS LIMITED
（全371頁）
【レポート詳細目次、データ項目一覧は当ページ下を参照ください】
Table of Contents (英文詳細目次）
1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 INCLUSIONS & EXCLUSIONS
1.4 MARKET SCOPE
1.4.1 MARKETS COVERED
1.4.2 REGIONS COVERED
1.4.3 YEARS CONSIDERED
1.4.4 CURRENCY CONSIDERED
1.5 RESEARCH LIMITATIONS
1.6 STAKEHOLDERS
1.7 SUMMARY OF CHANGES
1.8 RECESSION IMPACT: VACCINES MARKET
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.2 RESEARCH APPROACH
・ FIGURE 1 RESEARCH DESIGN
2.2.1 SECONDARY DATA
2.2.2 PRIMARY DATA
・ FIGURE 2 BREAKDOWN OF PRIMARIES
2.2.2.1 PRIMARY INSIGHTS
・ FIGURE 3 KEY INSIGHTS FROM PRIMARY EXPERTS
2.3 MARKET SIZE ESTIMATION
・ FIGURE 4 MARKET SIZE ESTIMATION: VACCINES MARKET, 2022
・ FIGURE 5 TOTAL REVENUE: VACCINES MARKET
・ FIGURE 6 REVENUE SHARE OF PFIZER INC., 2022
2.3.1 SEGMENTAL ASSESSMENT
・ FIGURE 7 TOP-DOWN APPROACH
2.4 GROWTH RATE ASSUMPTIONS
・ FIGURE 8 CAGR PROJECTION: VACCINES MARKET
・ FIGURE 9 GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, CHALLENGES, AND OPPORTUNITIES
2.5 STUDY ASSUMPTIONS
2.6 MARKET BREAKDOWN AND DATA TRIANGULATION
・ FIGURE 10 DATA TRIANGULATION METHODOLOGY
2.7 RISK ASSESSMENT
2.8 IMPACT OF RECESSION IN VACCINES MARKET
・ TABLE 1 GLOBAL INFLATION RATE PROJECTION, 2024–2028 (% GROWTH)
・ TABLE 2 US HEALTH EXPENDITURE, 2019–2022 (USD MILLION)
・ TABLE 3 US HEALTH EXPENDITURE, 2023–2027 (USD MILLION)
3 EXECUTIVE SUMMARY
・ FIGURE 11 VACCINES MARKET, BY TECHNOLOGY, 2023 VS. 2028 (USD BILLION)
・ FIGURE 12 VACCINES MARKET, BY TYPE, 2023 VS. 2028 (USD BILLION)
・ FIGURE 13 VACCINES MARKET, BY DISEASE INDICATION, 2023 VS. 2028 (USD BILLION)
・ FIGURE 14 VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2023 VS. 2028 (USD BILLION)
・ FIGURE 15 VACCINES MARKET, BY END USER, 2023 VS. 2028 (USD BILLION)
・ FIGURE 16 GEOGRAPHICAL SNAPSHOT OF VACCINES MARKET
4 PREMIUM INSIGHTS
4.1 VACCINES MARKET OVERVIEW
・ FIGURE 17 RISING PREVALENCE OF INFECTIOUS DISEASES TO DRIVE MARKET
4.2 NORTH AMERICA: VACCINES MARKET, BY TECHNOLOGY AND COUNTRY, 2022
・ FIGURE 18 M-RNA VACCINES AND US ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN VACCINES MARKET IN 2022
4.3 VACCINES MARKET, BY TECHNOLOGY, 2023 VS. 2028
・ FIGURE 19 M-RNA VACCINES TO DOMINATE MARKET IN 2028
4.4 GEOGRAPHICAL GROWTH OPPORTUNITIES: VACCINES MARKET
・ FIGURE 20 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
・ FIGURE 21 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES: VACCINES MARKET
・ TABLE 4 IMPACT ANALYSIS: VACCINES MARKET
5.2.1 DRIVERS
5.2.1.1 STRONG EMPHASIS ON LAUNCH OF NOVEL VACCINES
5.2.1.2 RISING PREVALENCE OF INFECTIOUS DISEASES
・ FIGURE 22 INCIDENCE OF TUBERCULOSIS IN US, 2017–2021
5.2.1.3 INCREASING NUMBER OF IMMUNIZATION PROGRAMS
5.2.1.4 ADVANCEMENTS IN VACCINE TECHNOLOGY
5.2.1.5 ROBUST GOVERNMENT SUPPORT AND FUNDING FOR VACCINE DEVELOPMENT 75
・ TABLE 5 NIH FUNDING FOR VACCINE RESEARCH, 2020–2024 (USD MILLION)
5.2.2 RESTRAINTS
5.2.2.1 HIGH COST OF VACCINE DEVELOPMENT
5.2.3 OPPORTUNITIES
5.2.3.1 INCREASED FOCUS ON THERAPEUTIC VACCINES
5.2.3.2 EXTENSIVE R&D FOR VACCINES AND INCREASED INVESTMENTS IN CLINICAL TRIALS
5.2.4 CHALLENGES
5.2.4.1 STRINGENT REGULATORY PROCESSES
5.2.4.2 FREQUENT PRODUCT RECALLS
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
・ FIGURE 23 REVENUE SHIFTS AND NEW REVENUE POCKETS FOR VACCINE PROVIDERS
5.4 PRICING ANALYSIS
5.4.1 AVERAGE SELLING PRICE OF PRODUCTS, BY KEY PLAYERS
・ TABLE 6 AVERAGE SELLING PRICE OF PEDIATRIC VACCINES
・ TABLE 7 AVERAGE SELLING PRICE OF ADULT VACCINES
5.4.2 AVERAGE SELLING PRICE, BY PRODUCT TYPE
・ TABLE 8 AVERAGE SELLING PRICE OF CONJUGATE VACCINES
・ TABLE 9 AVERAGE SELLING PRICE OF RECOMBINANT VACCINES
・ TABLE 10 AVERAGE SELLING PRICE OF INACTIVATED & SUBUNIT VACCINES
・ TABLE 11 AVERAGE SELLING PRICE OF LIVE ATTENUTAED VACCINES
・ TABLE 12 AVERAGE SELLING PRICE OF TOXOID VACCINES
・ TABLE 13 AVERAGE SELLING PRICE OF M-RNA VACCINES
5.4.3 AVERAGE SELLING PRICE TREND
5.5 TECHNOLOGY ANALYSIS
5.6 VALUE CHAIN ANALYSIS
・ FIGURE 24 VALUE CHAIN ANALYSIS: RAW MATERIAL AND MANUFACTURING PHASES TO CONTRIBUTE MAXIMUM VALUE
5.7 PIPELINE ANALYSIS
・ FIGURE 25 CLINICAL TRIALS IN VACCINES MARKET
・ FIGURE 26 VACCINES MARKET IN CLINICAL TRIALS, BY DISEASE INDICATION
・ TABLE 14 PIPELINE PRODUCTS UNDER PHASE-2 AND PHASE-3 CLINICAL TRIALS
5.7.1 KEY PIPELINE PRODUCTS
・ TABLE 15 KEY PIPELINE VACCINES: GSK PL
・ TABLE 16 KEY PIPELINE VACCINES: MERCK & CO., INC.
・ TABLE 17 KEY PIPELINE VACCINES: PFIZER, INC.
・ TABLE 18 KEY PIPELINE VACCINES: SANOFI S.A.
5.8 ECOSYSTEM MARKET/MAP
・ FIGURE 27 ECOSYSTEM MARKET/MAP
・ TABLE 19 ROLE IN ECOSYSTEM: VACCINES MARKET
5.9 REGULATORY ANALYSIS
5.9.1 REGULATORY LANDSCAPE FOR VACCINES
5.9.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
・ TABLE 20 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
・ TABLE 21 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
・ TABLE 22 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
・ TABLE 23 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
・ TABLE 24 MIDDLE EAST: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
・ TABLE 25 AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.10 PORTER’S FIVE FORCES ANALYSIS
・ TABLE 26 PORTER’S FIVE FORCES ANALYSIS
5.10.1 THREAT OF NEW ENTRANTS
5.10.2 THREAT OF SUBSTITUTES
5.10.3 BARGAINING POWER OF SUPPLIERS
5.10.4 BARGAINING POWER OF BUYERS 99
5.10.5 INTENSITY OF COMPETITIVE RIVALRY
5.11 PATENT ANALYSIS
・ FIGURE 28 PATENT APPLICATIONS FOR VACCINES, SEPTEMBER 2013–SEPTEMBER 2023
・ TABLE 27 INDICATIVE LIST OF PATENTS IN VACCINES MARKET
5.12 KEY CONFERENCES & EVENTS
・ TABLE 28 DETAILED LIST OF KEY CONFERENCES & EVENTS, 2023–2024
5.13 KEY STAKEHOLDERS & BUYING CRITERIA
5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS
・ FIGURE 29 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF VACCINES
5.13.2 KEY BUYING CRITERIA
・ FIGURE 30 KEY BUYING CRITERIA FOR END USERS IN VACCINES MARKET
6 VACCINES MARKET, BY TECHNOLOGY
6.1 INTRODUCTION
・ TABLE 29 VACCINES MARKET, BY TECHNOLOGY, 2021–2028 (USD BILLION)
6.2 CONJUGATE VACCINES
6.2.1 INCREASING PUBLIC-PRIVATE PARTNERSHIPS TO DRIVE MARKET
・ TABLE 30 VACCINES MARKET FOR CONJUGATE VACCINES, BY REGION, 2021–2028 (USD BILLION)
・ TABLE 31 NORTH AMERICA: VACCINES MARKET FOR CONJUGATE VACCINES, BY COUNTRY, 2021–2028 (USD BILLION)
・ TABLE 32 EUROPE: VACCINES MARKET FOR CONJUGATE VACCINES, BY COUNTRY, 2021–2028 (USD BILLION)
・ TABLE 33 ASIA PACIFIC: VACCINES MARKET FOR CONJUGATE VACCINES, BY COUNTRY, 2021–2028 (USD BILLION)
・ TABLE 34 LATIN AMERICA: VACCINES MARKET FOR CONJUGATE VACCINES, BY COUNTRY, 2021–2028 (USD BILLION)
6.3 RECOMBINANT VACCINES
6.3.1 LESSER POST-VACCINATION REACTIONS AND REDUCED NEED FOR BOOSTER DOSES TO DRIVE MARKET
・ TABLE 35 EXAMPLES OF RECOMBINANT VACCINES
・ TABLE 36 VACCINES MARKET FOR RECOMBINANT VACCINES, BY REGION, 2021–2028 (USD BILLION)
・ TABLE 37 NORTH AMERICA: VACCINES MARKET FOR RECOMBINANT VACCINES, BY COUNTRY, 2021–2028 (USD BILLION)
・ TABLE 38 EUROPE: VACCINES MARKET FOR RECOMBINANT VACCINES, BY COUNTRY, 2021–2028 (USD BILLION)
・ TABLE 39 ASIA PACIFIC: VACCINES MARKET FOR RECOMBINANT VACCINES, BY COUNTRY, 2021–2028 (USD BILLION)
・ TABLE 40 LATIN AMERICA: VACCINES MARKET FOR RECOMBINANT VACCINES, BY COUNTRY, 2021–2028 (USD BILLION)
6.4 INACTIVATED & SUBUNIT VACCINES
6.4.1 EASE OF STORAGE AND TRANSPORTATION TO DRIVE MARKET
・ TABLE 41 EXAMPLES OF INACTIVATED & SUBUNIT VACCINES
・ TABLE 42 VACCINES MARKET FOR INACTIVATED & SUBUNIT VACCINES, BY REGION, 2021–2028 (USD BILLION)
・ TABLE 43 NORTH AMERICA: VACCINES MARKET FOR INACTIVATED & SUBUNIT VACCINES, BY COUNTRY, 2021–2028 (USD BILLION)
・ TABLE 44 EUROPE: VACCINES MARKET FOR INACTIVATED & SUBUNIT VACCINES, BY COUNTRY, 2021–2028 (USD BILLION)
・ TABLE 45 ASIA PACIFIC: VACCINES MARKET FOR INACTIVATED & SUBUNIT VACCINES, BY COUNTRY, 2021–2028 (USD BILLION)
・ TABLE 46 LATIN AMERICA: VACCINES MARKET FOR INACTIVATED & SUBUNIT VACCINES, BY COUNTRY, 2021–2028 (USD BILLION)
6.5 LIVE ATTENUATED VACCINES
6.5.1 HIGH COST OF STORAGE AND LIMITED FINANCIAL RESOURCES OF DISTRIBUTORS TO LIMIT MARKET
・ TABLE 47 EXAMPLES OF LIVE ATTENUATED VACCINES
・ TABLE 48 VACCINES MARKET FOR LIVE ATTENUATED VACCINES, BY REGION, 2021–2028 (USD BILLION)
・ TABLE 49 NORTH AMERICA: VACCINES MARKET FOR LIVE ATTENUATED VACCINES, BY COUNTRY, 2021–2028 (USD BILLION)
・ TABLE 50 EUROPE: VACCINES MARKET FOR LIVE ATTENUATED VACCINES, BY COUNTRY, 2021–2028 (USD BILLION)
・ TABLE 51 ASIA PACIFIC: VACCINES MARKET FOR LIVE ATTENUATED VACCINES, BY COUNTRY, 2021–2028 (USD BILLION)
・ TABLE 52 LATIN AMERICA: VACCINES MARKET FOR LIVE ATTENUATED VACCINES, BY COUNTRY, 2021–2028 (USD BILLION)
6.6 TOXOID VACCINES
6.6.1 RISING PREVALENCE OF BACTERIAL INFECTIONS AMONG INFANTS AND CHILDREN TO DRIVE MARKET
・ TABLE 53 EXAMPLES OF TOXOID VACCINES 120
・ TABLE 54 VACCINES MARKET FOR TOXOID VACCINES, BY REGION, 2021–2028 (USD BILLION)
・ TABLE 55 NORTH AMERICA: VACCINES MARKET FOR TOXOID VACCINES, BY COUNTRY, 2021–2028 (USD BILLION)
・ TABLE 56 EUROPE: VACCINES MARKET FOR TOXOID VACCINES, BY COUNTRY, 2021–2028 (USD BILLION)
・ TABLE 57 ASIA PACIFIC: VACCINES MARKET FOR TOXOID VACCINES, BY COUNTRY, 2021–2028 (USD BILLION)
・ TABLE 58 LATIN AMERICA: VACCINES MARKET FOR TOXOID VACCINES, BY COUNTRY, 2021–2028 (USD BILLION)
6.7 VIRAL VECTOR VACCINES
6.7.1 INCREASING INVESTMENT IN NOVEL VACCINE DEVELOPMENT TO DRIVE MARKET
・ TABLE 59 VACCINES MARKET FOR VIRAL VECTOR VACCINES, BY REGION, 2021–2028 (USD BILLION)
・ TABLE 60 NORTH AMERICA: VACCINES MARKET FOR VIRAL VECTOR VACCINES, BY COUNTRY, 2021–2028 (USD BILLION)
・ TABLE 61 EUROPE: VACCINES MARKET FOR VIRAL VECTOR VACCINES, BY COUNTRY, 2021–2028 (USD BILLION)
・ TABLE 62 ASIA PACIFIC: VACCINES MARKET FOR VIRAL VECTOR VACCINES, BY COUNTRY, 2021–2028 (USD BILLION)
・ TABLE 63 LATIN AMERICA: VACCINES MARKET FOR VIRAL VECTOR VACCINES, BY COUNTRY, 2021–2028 (USD BILLION)
6.8 M-RNA VACCINES
6.8.1 INCREASING INVESTMENT IN M-RNA VACCINE DEVELOPMENT TO DRIVE MARKET
・ TABLE 64 VACCINES MARKET FOR M-RNA VACCINES, BY REGION, 2021–2028 (USD BILLION)
・ TABLE 65 NORTH AMERICA: VACCINES MARKET FOR M-RNA VACCINES, BY COUNTRY, 2021–2028 (USD BILLION)
・ TABLE 66 EUROPE: VACCINES MARKET FOR M-RNA VACCINES, BY COUNTRY, 2021–2028 (USD BILLION)
・ TABLE 67 ASIA PACIFIC: VACCINES MARKET FOR M-RNA VACCINES, BY COUNTRY, 2021–2028 (USD BILLION)
・ TABLE 68 LATIN AMERICA: VACCINES MARKET FOR M-RNA VACCINES, BY COUNTRY, 2021–2028 (USD BILLION)
6.9 OTHER VACCINES
・ TABLE 69 VACCINES MARKET FOR OTHER VACCINES, BY REGION, 2021–2028 (USD BILLION)
・ TABLE 70 NORTH AMERICA: VACCINES MARKET FOR OTHER VACCINES, BY COUNTRY, 2021–2028 (USD BILLION)
・ TABLE 71 EUROPE: VACCINES MARKET FOR OTHER VACCINES, BY COUNTRY, 2021–2028 (USD BILLION)
・ TABLE 72 ASIA PACIFIC: VACCINES MARKET FOR OTHER VACCINES, BY COUNTRY, 2021–2028 (USD BILLION)
・ TABLE 73 LATIN AMERICA: VACCINES MARKET FOR OTHER VACCINES, BY COUNTRY, 2021–2028 (USD BILLION)
7 VACCINES MARKET, BY TYPE
7.1 INTRODUCTION
・ TABLE 74 VACCINES MARKET, BY TYPE, 2021–2028 (USD BILLION)
7.2 MONOVALENT VACCINES
7.2.1 INCREASING INVESTMENT IN R&D AND RISING PREVALENCE OF INFECTIOUS DISEASES TO DRIVE MARKET 134
・ TABLE 75 EXAMPLES OF MONOVALENT VACCINES
・ TABLE 76 VACCINES MARKET FOR MONOVALENT VACCINES, BY REGION, 2021–2028 (USD BILLION)
・ TABLE 77 NORTH AMERICA: VACCINES MARKET FOR MONOVALENT VACCINES, BY COUNTRY, 2021–2028 (USD BILLION)
・ TABLE 78 EUROPE: VACCINES MARKET FOR MONOVALENT VACCINES, BY COUNTRY, 2021–2028 (USD BILLION)
・ TABLE 79 ASIA PACIFIC: VACCINES MARKET FOR MONOVALENT VACCINES, BY COUNTRY, 2021–2028 (USD BILLION)
・ TABLE 80 LATIN AMERICA: VACCINES MARKET FOR MONOVALENT VACCINES, BY COUNTRY, 2021–2028 (USD BILLION)
7.3 MULTIVALENT VACCINES
7.3.1 INCREASED NEED FOR IMMUNIZATION AND COST-EFFECTIVENESS TO DRIVE MARKET
・ TABLE 81 EXAMPLES OF MULTIVALENT VACCINES
・ TABLE 82 VACCINES MARKET FOR MULTIVALENT VACCINES, BY REGION, 2021–2028 (USD BILLION)
・ TABLE 83 NORTH AMERICA: VACCINES MARKET FOR MULTIVALENT VACCINES, BY COUNTRY, 2021–2028 (USD BILLION)
・ TABLE 84 EUROPE: VACCINES MARKET FOR MULTIVALENT VACCINES, BY COUNTRY, 2021–2028 (USD BILLION)
・ TABLE 85 ASIA PACIFIC: VACCINES MARKET FOR MULTIVALENT VACCINES, BY COUNTRY, 2021–2028 (USD BILLION)
・ TABLE 86 LATIN AMERICA: VACCINES MARKET FOR MULTIVALENT VACCINES, BY COUNTRY, 2021–2028 (USD BILLION)
8 VACCINES MARKET, BY DISEASE INDICATION
8.1 INTRODUCTION
・ TABLE 87 VACCINES MARKET, BY DISEASE INDICATION, 2021–2028 (USD BILLION)
8.2 PNEUMOCOCCAL DISEASE
8.2.1 INCREASING INCIDENCE OF PNEUMONIA IN CHILDREN TO DRIVE MARKET
・ TABLE 88 LIST OF COMMERCIALLY AVAILABLE PNEUMOCOCCAL DISEASE VACCINES
・ TABLE 89 VACCINES MARKET FOR PNEUMOCOCCAL DISEASE, BY REGION, 2021–2028 (USD BILLION)
・ TABLE 90 NORTH AMERICA: VACCINES MARKET FOR PNEUMOCOCCAL DISEASE, BY COUNTRY, 2021–2028 (USD BILLION)
・ TABLE 91 EUROPE: VACCINES MARKET FOR PNEUMOCOCCAL DISEASE, BY COUNTRY, 2021–2028 (USD BILLION)
・ TABLE 92 ASIA PACIFIC: VACCINES MARKET FOR PNEUMOCOCCAL DISEASE, BY COUNTRY, 2021–2028 (USD BILLION)
・ TABLE 93 LATIN AMERICA: VACCINES MARKET FOR PNEUMOCOCCAL DISEASE, BY COUNTRY, 2021–2028 (USD BILLION)
8.3 INFLUENZA 148
8.3.1 RISING NEED FOR IMMUNIZATION AGAINST VIRAL INFECTIONS TO DRIVE MARKET
・ TABLE 94 LIST OF COMMERCIALLY AVAILABLE INFLUENZA VACCINES
・ TABLE 95 VACCINES MARKET FOR INFLUENZA, BY REGION, 2021–2028 (USD BILLION)
・ TABLE 96 NORTH AMERICA: VACCINES MARKET FOR INFLUENZA, BY COUNTRY, 2021–2028 (USD BILLION)
・ TABLE 97 EUROPE: VACCINES MARKET FOR INFLUENZA, BY COUNTRY, 2021–2028 (USD BILLION)
・ TABLE 98 ASIA PACIFIC: VACCINES MARKET FOR INFLUENZA, BY COUNTRY, 2021–2028 (USD BILLION)
・ TABLE 99 LATIN AMERICA: VACCINES MARKET FOR INFLUENZA, BY COUNTRY, 2021–2028 (USD BILLION)
8.4 COMBINATION VACCINES
8.4.1 GROWING DEMAND FOR ALL-IN-ONE VACCINE TO DRIVE MARKET
・ TABLE 100 LIST OF COMMERCIALLY AVAILABLE COMBINATION VACCINES
・ TABLE 101 VACCINES MARKET FOR COMBINATION VACCINES, BY REGION, 2021–2028 (USD BILLION)
・ TABLE 102 NORTH AMERICA: VACCINES MARKET FOR COMBINATION VACCINES, BY COUNTRY, 2021–2028 (USD BILLION)
・ TABLE 103 EUROPE: VACCINES MARKET FOR COMBINATION VACCINES, BY COUNTRY, 2021–2028 (USD BILLION)
・ TABLE 104 ASIA PACIFIC: VACCINES MARKET FOR COMBINATION VACCINES, BY COUNTRY, 2021–2028 (USD BILLION)
・ TABLE 105 LATIN AMERICA: VACCINES MARKET FOR COMBINATION VACCINES, BY COUNTRY, 2021–2028 (USD BILLION)
8.5 HPV
8.5.1 GROWING INCIDENCE OF SEXUALLY TRANSMITTED DISEASES TO DRIVE MARKET
・ TABLE 106 LIST OF COMMERCIALLY AVAILABLE HPV VACCINES
・ TABLE 107 VACCINES MARKET FOR HPV, BY REGION, 2021–2028 (USD BILLION)
・ TABLE 108 NORTH AMERICA: VACCINES MARKET FOR HPV, BY COUNTRY, 2021–2028 (USD BILLION)
・ TABLE 109 EUROPE: VACCINES MARKET FOR HPV, BY COUNTRY, 2021–2028 (USD BILLION)
・ TABLE 110 ASIA PACIFIC: VACCINES MARKET FOR HPV, BY COUNTRY, 2021–2028 (USD BILLION)
・ TABLE 111 LATIN AMERICA: VACCINES MARKET FOR HPV, BY COUNTRY, 2021–2028 (USD BILLION)
8.6 MENINGOCOCCAL DISEASE
8.6.1 INCREASING INITIATIVES BY GOVERNMENT AND NON-GOVERNMENT ORGANIZATIONS TO DRIVE MARKET
・ TABLE 112 LIST OF COMMERCIALLY AVAILABLE MENINGOCOCCAL DISEASE VACCINES
・ TABLE 113 VACCINES MARKET FOR MENINGOCOCCAL DISEASE, BY REGION, 2021–2028 (USD BILLION)
・ TABLE 114 NORTH AMERICA: VACCINES MARKET FOR MENINGOCOCCAL DISEASE, BY COUNTRY, 2021–2028 (USD BILLION)
・ TABLE 115 EUROPE: VACCINES MARKET FOR MENINGOCOCCAL DISEASE, BY COUNTRY, 2021–2028 (USD BILLION)
・ TABLE 116 ASIA PACIFIC: VACCINES MARKET FOR MENINGOCOCCAL DISEASE, BY COUNTRY, 2021–2028 (USD BILLION)
・ TABLE 117 LATIN AMERICA: VACCINES MARKET FOR MENINGOCOCCAL DISEASE, BY COUNTRY, 2021–2028 (USD BILLION)
8.7 HERPES ZOSTER
8.7.1 INCREASING INVESTMENT IN NOVEL VACCINE DEVELOPMENT TO DRIVE MARKET
・ TABLE 118 VACCINES MARKET FOR HERPES ZOSTER, BY REGION, 2021–2028 (USD BILLION)
・ TABLE 119 NORTH AMERICA: VACCINES MARKET FOR HERPES ZOSTER, BY COUNTRY, 2021–2028 (USD BILLION)
・ TABLE 120 EUROPE: VACCINES MARKET FOR HERPES ZOSTER, BY COUNTRY, 2021–2028 (USD BILLION)
・ TABLE 121 ASIA PACIFIC: VACCINES MARKET FOR HERPES ZOSTER, BY COUNTRY, 2021–2028 (USD BILLION)
・ TABLE 122 LATIN AMERICA: VACCINES MARKET FOR HERPES ZOSTER, BY COUNTRY, 2021–2028 (USD BILLION)
8.8 ROTAVIRUS 166
8.8.1 GROWING FOCUS OF GOVERNMENT AND NON-GOVERNMENT BODIES ON ROTAVIRUS PREVENTION TO DRIVE MARKET
・ TABLE 123 LIST OF COMMERCIALLY AVAILABLE ROTAVIRUS VACCINES
・ TABLE 124 VACCINES MARKET FOR ROTAVIRUS, BY REGION, 2021–2028 (USD BILLION)
・ TABLE 125 NORTH AMERICA: VACCINES MARKET FOR ROTAVIRUS, BY COUNTRY, 2021–2028 (USD BILLION)
・ TABLE 126 EUROPE: VACCINES MARKET FOR ROTAVIRUS, BY COUNTRY, 2021–2028 (USD BILLION)
・ TABLE 127 ASIA PACIFIC: VACCINES MARKET FOR ROTAVIRUS, BY COUNTRY, 2021–2028 (USD BILLION)
・ TABLE 128 LATIN AMERICA: VACCINES MARKET FOR ROTAVIRUS, BY COUNTRY, 2021–2028 (USD BILLION)
8.9 MMR
8.9.1 RISING INCIDENCE OF MEASLES, MUMPS, AND RUBELLA TO DRIVE MARKET
・ TABLE 129 LIST OF COMMERCIALLY AVAILABLE MMR VACCINES
・ TABLE 130 VACCINES MARKET FOR MMR, BY REGION, 2021–2028 (USD BILLION)
・ TABLE 131 NORTH AMERICA: VACCINES MARKET FOR MMR, BY COUNTRY, 2021–2028 (USD BILLION)
・ TABLE 132 EUROPE: VACCINES MARKET FOR MMR, BY COUNTRY, 2021–2028 (USD BILLION)
・ TABLE 133 ASIA PACIFIC: VACCINES MARKET FOR MMR, BY COUNTRY, 2021–2028 (USD BILLION)
・ TABLE 134 LATIN AMERICA: VACCINES MARKET FOR MMR, BY COUNTRY, 2021–2028 (USD BILLION)
8.10 VARICELLA 173
8.10.1 INCREASING PROMOTION OF IMMUNIZATION PROGRAMS TO DRIVE MARKET
・ TABLE 135 LIST OF COMMERCIALLY AVAILABLE VARICELLA VACCINES
・ TABLE 136 VACCINES MARKET FOR VARICELLA, BY REGION, 2021–2028 (USD BILLION)
・ TABLE 137 NORTH AMERICA: VACCINES MARKET FOR VARICELLA, BY COUNTRY, 2021–2028 (USD BILLION)
・ TABLE 138 EUROPE: VACCINES MARKET FOR VARICELLA, BY COUNTRY, 2021–2028 (USD BILLION)
・ TABLE 139 ASIA PACIFIC: VACCINES MARKET FOR VARICELLA, BY COUNTRY, 2021–2028 (USD BILLION)
・ TABLE 140 LATIN AMERICA: VACCINES MARKET FOR VARICELLA, BY COUNTRY, 2021–2028 (USD BILLION)
8.11 HEPATITIS 176
8.11.1 LOW SOCIO-ECONOMIC STANDARDS OF LIVING AND HIGH CONTAMINATION IN DRINKING WATER TO DRIVE MARKET
・ TABLE 141 LIST OF COMMERCIALLY AVAILABLE HEPATITIS VACCINES
・ TABLE 142 VACCINES MARKET FOR HEPATITIS, BY REGION, 2021–2028 (USD MILLION)
・ TABLE 143 NORTH AMERICA: VACCINES MARKET FOR HEPATITIS, BY COUNTRY, 2021–2028 (USD BILLION)
・ TABLE 144 EUROPE: VACCINES MARKET FOR HEPATITIS, BY COUNTRY, 2021–2028 (USD BILLION)
・ TABLE 145 ASIA PACIFIC: VACCINES MARKET FOR HEPATITIS, BY COUNTRY, 2021–2028 (USD BILLION)
・ TABLE 146 LATIN AMERICA: VACCINES MARKET FOR HEPATITIS, BY COUNTRY, 2021–2028 (USD BILLION)
8.12 DTP
8.12.1 INCREASED OCCURRENCE OF DIPHTHERIA, TETANUS, AND PERTUSSIS IN EMERGING ECONOMIES TO DRIVE MARKET
・ TABLE 147 LIST OF COMMERCIALLY AVAILABLE DTP VACCINES
・ TABLE 148 VACCINES MARKET FOR DTP, BY REGION, 2021–2028 (USD BILLION)
・ TABLE 149 NORTH AMERICA: VACCINES MARKET FOR DTP, BY COUNTRY, 2021–2028 (USD BILLION)
・ TABLE 150 EUROPE: VACCINES MARKET FOR DTP, BY COUNTRY, 2021–2028 (USD BILLION)
・ TABLE 151 ASIA PACIFIC: VACCINES MARKET FOR DTP, BY COUNTRY, 2021–2028 (USD BILLION)
・ TABLE 152 LATIN AMERICA: VACCINES MARKET FOR DTP, BY COUNTRY, 2021–2028 (USD BILLION)
8.13 POLIO
8.13.1 INCREASING GOVERNMENT INITIATIVES AND IMMUNIZATION PROGRAMS TO DRIVE MARKET
・ TABLE 153 VACCINES MARKET FOR POLIO, BY REGION, 2021–2028 (USD BILLION)
・ TABLE 154 NORTH AMERICA: VACCINES MARKET FOR POLIO, BY COUNTRY, 2021–2028 (USD BILLION)
・ TABLE 155 EUROPE: VACCINES MARKET FOR POLIO, BY COUNTRY, 2021–2028 (USD BILLION)
・ TABLE 156 ASIA PACIFIC: VACCINES MARKET FOR POLIO, BY COUNTRY, 2021–2028 (USD BILLION)
・ TABLE 157 LATIN AMERICA: VACCINES MARKET FOR POLIO, BY COUNTRY, 2021–2028 (USD BILLION)
8.14 OTHER DISEASE INDICATIONS
・ FIGURE 31 NUMBER OF COVID-19 CASES IN US, 2020–2023
・ TABLE 158 LIST OF COMMERCIALLY AVAILABLE VACCINES FOR OTHER DISEASE INDICATIONS
・ TABLE 159 VACCINES MARKET FOR OTHER DISEASE INDICATIONS, BY REGION, 2021–2028 (USD BILLION)
・ TABLE 160 NORTH AMERICA: VACCINES MARKET FOR OTHER DISEASE INDICATIONS, BY COUNTRY, 2021–2028 (USD BILLION)
・ TABLE 161 EUROPE: VACCINES MARKET FOR OTHER DISEASE INDICATIONS, BY COUNTRY, 2021–2028 (USD BILLION)
・ TABLE 162 ASIA PACIFIC: VACCINES MARKET FOR OTHER DISEASE INDICATIONS, BY COUNTRY, 2021–2028 (USD BILLION)
・ TABLE 163 LATIN AMERICA: VACCINES MARKET FOR OTHER DISEASE INDICATIONS, BY COUNTRY, 2021–2028 (USD BILLION)
9 VACCINES MARKET, BY ROUTE OF ADMINISTRATION
9.1 INTRODUCTION
・ TABLE 164 VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD BILLION)
9.2 INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION
9.2.1 EASIER ABSORPTION INTO BLOODSTREAM AND BETTER IMMUNE RESPONSE TO DRIVE MARKET
・ TABLE 165 ADVANTAGES AND DISADVANTAGES OF INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION
・ TABLE 166 VACCINES MARKET FOR INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION, BY REGION, 2021–2028 (USD BILLION)
・ TABLE 167 NORTH AMERICA: VACCINES MARKET FOR INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION, BY COUNTRY, 2021–2028 (USD BILLION)
・ TABLE 168 EUROPE: VACCINES MARKET FOR INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION, BY COUNTRY, 2021–2028 (USD BILLION)
・ TABLE 169 ASIA PACIFIC: VACCINES MARKET FOR INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION, BY COUNTRY, 2021–2028 (USD BILLION)
・ TABLE 170 LATIN AMERICA: VACCINES MARKET FOR INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION, BY COUNTRY, 2021–2028 (USD BILLION)
9.3 ORAL ADMINISTRATION
9.3.1 EASE OF ADMINISTRATION AND REDUCED RISK OF BLOOD-TRANSMITTED INFECTIONS TO DRIVE MARKET
・ TABLE 171 VACCINES MARKET FOR ORAL ADMINISTRATION, BY REGION, 2021–2028 (USD BILLION)
・ TABLE 172 NORTH AMERICA: VACCINES MARKET FOR ORAL ADMINISTRATION, BY COUNTRY, 2021–2028 (USD BILLION)
・ TABLE 173 EUROPE: VACCINES MARKET FOR ORAL ADMINISTRATION, BY COUNTRY, 2021–2028 (USD BILLION)
・ TABLE 174 ASIA PACIFIC: VACCINES MARKET FOR ORAL ADMINISTRATION, BY COUNTRY, 2021–2028 (USD BILLION)
・ TABLE 175 LATIN AMERICA: VACCINES MARKET FOR ORAL ADMINISTRATION, BY COUNTRY, 2021–2028 (USD BILLION)
9.4 OTHER ROUTES OF ADMINISTRATION
・ TABLE 176 VACCINES MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY REGION, 2021–2028 (USD BILLION)
・ TABLE 177 NORTH AMERICA: VACCINES MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2021–2028 (USD BILLION)
・ TABLE 178 EUROPE: VACCINES MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2021–2028 (USD BILLION)
・ TABLE 179 ASIA PACIFIC: VACCINES MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2021–2028 (USD BILLION)
・ TABLE 180 LATIN AMERICA: VACCINES MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2021–2028 (USD BILLION)
10 VACCINES MARKET, BY END USER
10.1 INTRODUCTION
・ TABLE 181 VACCINES MARKET, BY END USER, 2021–2028 (USD BILLION)
10.2 PEDIATRIC VACCINES
10.2.1 INCREASED INITIATIVES BY GOVERNMENT AND NON-GOVERNMENT BODIES TO DRIVE MARKET
・ TABLE 182 VACCINES MARKET FOR PEDIATRIC VACCINES, BY REGION, 2021–2028 (USD BILLION)
・ TABLE 183 NORTH AMERICA: VACCINES MARKET FOR PEDIATRIC VACCINES, BY COUNTRY, 2021–2028 (USD BILLION)
・ TABLE 184 EUROPE: VACCINES MARKET FOR PEDIATRIC VACCINES, BY COUNTRY, 2021–2028 (USD BILLION)
・ TABLE 185 ASIA PACIFIC: VACCINES MARKET FOR PEDIATRIC VACCINES, BY COUNTRY, 2021–2028 (USD BILLION)
・ TABLE 186 LATIN AMERICA: VACCINES MARKET FOR PEDIATRIC VACCINES, BY COUNTRY, 2021–2028 (USD BILLION)
10.3 ADULT VACCINES
10.3.1 ADULT VACCINES SEGMENT TO COMMAND LARGER MARKET SHARE DURING FORECAST PERIOD
・ TABLE 187 VACCINES MARKET FOR ADULT VACCINES, BY REGION, 2021–2028 (USD BILLION)
・ TABLE 188 NORTH AMERICA: VACCINES MARKET FOR ADULT VACCINES, BY COUNTRY, 2021–2028 (USD BILLION)
・ TABLE 189 EUROPE: VACCINES MARKET FOR ADULT VACCINES, BY COUNTRY, 2021–2028 (USD BILLION)
・ TABLE 190 ASIA PACIFIC: VACCINES MARKET FOR ADULT VACCINES, BY COUNTRY, 2021–2028 (USD BILLION)
・ TABLE 191 LATIN AMERICA: VACCINES MARKET FOR ADULT VACCINES, BY COUNTRY, 2021–2028 (USD BILLION)
11 VACCINES MARKET, BY REGION
11.1 INTRODUCTION
・ TABLE 192 VACCINES MARKET, BY REGION, 2021–2028 (USD BILLION)
11.2 NORTH AMERICA
・ FIGURE 32 NORTH AMERICA: VACCINES MARKET SNAPSHOT
・ TABLE 193 NORTH AMERICA: VACCINES MARKET, BY COUNTRY, 2021–2028 (USD BILLION)
・ TABLE 194 NORTH AMERICA: VACCINES MARKET, BY TECHNOLOGY, 2021–2028 (USD BILLION)
・ TABLE 195 NORTH AMERICA: VACCINES MARKET, BY TYPE, 2021–2028 (USD BILLION)
・ TABLE 196 NORTH AMERICA: VACCINES MARKET, BY DISEASE INDICATION, 2021–2028 (USD BILLION)
・ TABLE 197 NORTH AMERICA: VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD BILLION)
・ TABLE 198 NORTH AMERICA: VACCINES MARKET, BY END USER, 2021–2028 (USD BILLION)
11.3 NORTH AMERICA: RECESSION IMPACT
11.3.1 US
11.3.1.1 US TO DOMINATE NORTH AMERICAN VACCINES MARKET DURING FORECAST PERIOD
・ TABLE 199 US: VACCINES MARKET, BY TECHNOLOGY, 2021–2028 (USD BILLION)
・ TABLE 200 US: VACCINES MARKET, BY TYPE, 2021–2028 (USD BILLION)
・ TABLE 201 US: VACCINES MARKET, BY DISEASE INDICATION, 2021–2028 (USD BILLION)
・ TABLE 202 US: VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD BILLION)
・ TABLE 203 US: VACCINES MARKET, BY END USER, 2021–2028 (USD BILLION)
11.3.2 CANADA
11.3.2.1 HIGH INCIDENCE OF INFECTIOUS DISEASES TO DRIVE MARKET
・ TABLE 204 CANADA: VACCINES MARKET, BY TECHNOLOGY, 2021–2028 (USD BILLION)
・ TABLE 205 CANADA: VACCINES MARKET, BY TYPE, 2021–2028 (USD BILLION)
・ TABLE 206 CANADA: VACCINES MARKET, BY DISEASE INDICATION, 2021–2028 (USD BILLION)
・ TABLE 207 CANADA: VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD BILLION)
・ TABLE 208 CANADA: VACCINES MARKET, BY END USER, 2021–2028 (USD BILLION)
11.4 EUROPE
・ TABLE 209 EUROPE: VACCINES MARKET, BY COUNTRY, 2021–2028 (USD BILLION)
・ TABLE 210 EUROPE: VACCINES MARKET, BY TECHNOLOGY, 2021–2028 (USD BILLION)
・ TABLE 211 EUROPE: VACCINES MARKET, BY TYPE, 2021–2028 (USD BILLION)
・ TABLE 212 EUROPE: VACCINES MARKET, BY DISEASE INDICATION, 2021–2028 (USD BILLION)
・ TABLE 213 EUROPE VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD BILLION)
・ TABLE 214 EUROPE: VACCINES MARKET, BY END USER, 2021–2028 (USD BILLION)
11.5 EUROPE: RECESSION IMPACT
11.5.1 GERMANY
11.5.1.1 SIGNIFICANT R&D INVESTMENTS AND GROWING BIOTECHNOLOGY INDUSTRY TO DRIVE MARKET
・ TABLE 215 GERMANY: VACCINES MARKET, BY TECHNOLOGY, 2021–2028 (USD BILLION)
・ TABLE 216 GERMANY: VACCINES MARKET, BY TYPE, 2021–2028 (USD BILLION)
・ TABLE 217 GERMANY: VACCINES MARKET, BY DISEASE INDICATION, 2021–2028 (USD BILLION)
・ TABLE 218 GERMANY: VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD BILLION)
・ TABLE 219 GERMANY: VACCINES MARKET, BY END USER, 2021–2028 (USD BILLION)
11.5.2 UK
11.5.2.1 LAUNCH OF NEW PRODUCTS AND INCREASED FUNDING BY GOVERNMENT AND NON-GOVERNMENT ORGANIZATIONS TO DRIVE MARKET
・ TABLE 220 UK: VACCINES MARKET, BY TECHNOLOGY, 2021–2028 (USD BILLION)
・ TABLE 221 UK: VACCINES MARKET, BY TYPE, 2021–2028 (USD BILLION)
・ TABLE 222 UK: VACCINES MARKET, BY DISEASE INDICATION, 2021–2028 (USD BILLION)
・ TABLE 223 UK: VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD BILLION)
・ TABLE 224 UK: VACCINES MARKET, BY END USER, 2021–2028 (USD BILLION)
11.5.3 FRANCE
11.5.3.1 FAVORABLE GOVERNMENT INITIATIVES FOR MASS IMMUNIZATION TO DRIVE MARKET
・ TABLE 225 FRANCE: VACCINES MARKET, BY TECHNOLOGY, 2021–2028 (USD BILLION)
・ TABLE 226 FRANCE: VACCINES MARKET, BY TYPE, 2021–2028 (USD BILLION)
・ TABLE 227 FRANCE: VACCINES MARKET, BY DISEASE INDICATION, 2021–2028 (USD BILLION)
・ TABLE 228 FRANCE: VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD BILLION)
・ TABLE 229 FRANCE: VACCINES MARKET, BY END USER, 2021–2028 (USD BILLION)
11.5.4 ITALY
11.5.4.1 HIGHER INVESTMENTS BY COMPANIES FOR INCREASED PRODUCTION CAPACITIES TO DRIVE MARKET
・ TABLE 230 ITALY: VACCINES MARKET, BY TECHNOLOGY, 2021–2028 (USD BILLION)
・ TABLE 231 ITALY: VACCINES MARKET, BY TYPE, 2021–2028 (USD BILLION)
・ TABLE 232 ITALY: VACCINES MARKET, BY DISEASE INDICATION, 2021–2028 (USD BILLION)
・ TABLE 233 TALY: VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD BILLION)
・ TABLE 234 ITALY: VACCINES MARKET, BY END USER, 2021–2028 (USD BILLION)
11.5.5 SPAIN
11.5.5.1 RISING INVESTMENTS IN VACCINE DEVELOPMENT BY PRIVATE ORGANIZATIONS TO DRIVE MARKET
・ TABLE 235 SPAIN: VACCINES MARKET, BY TECHNOLOGY, 2021–2028 (USD BILLION)
・ TABLE 236 SPAIN: VACCINES MARKET, BY TYPE, 2021–2028 (USD BILLION)
・ TABLE 237 SPAIN: VACCINES MARKET, BY DISEASE INDICATION, 2021–2028 (USD BILLION)
・ TABLE 238 SPAIN: VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD BILLION)
・ TABLE 239 SPAIN: VACCINES MARKET, BY END USER, 2021–2028 (USD BILLION)
11.5.6 REST OF EUROPE
・ TABLE 240 REST OF EUROPE: VACCINES MARKET, BY TECHNOLOGY, 2021–2028 (USD BILLION)
・ TABLE 241 REST OF EUROPE: VACCINES MARKET, BY TYPE, 2021–2028 (USD BILLION)
・ TABLE 242 REST OF EUROPE: VACCINES MARKET, BY DISEASE INDICATION, 2021–2028 (USD BILLION)
・ TABLE 243 REST OF EUROPE: VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD BILLION)
・ TABLE 244 REST OF EUROPE: VACCINES MARKET, BY END USER, 2021–2028 (USD BILLION)
11.6 ASIA PACIFIC
・ FIGURE 33 ASIA PACIFIC: VACCINES MARKET SNAPSHOT
・ TABLE 245 ASIA PACIFIC: VACCINES MARKET, BY COUNTRY, 2021–2028 (USD BILLION)
・ TABLE 246 ASIA PACIFIC: VACCINES MARKET, BY TECHNOLOGY, 2021–2028 (USD BILLION)
・ TABLE 247 ASIA PACIFIC: VACCINES MARKET, BY TYPE, 2021–2028 (USD BILLION)
・ TABLE 248 ASIA PACIFIC: VACCINES MARKET, BY DISEASE INDICATION, 2021–2028 (USD BILLION)
・ TABLE 249 ASIA PACIFIC: VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD BILLION)
・ TABLE 250 ASIA PACIFIC: VACCINES MARKET, BY END USER, 2021–2028 (USD BILLION)
11.7 ASIA PACIFIC: RECESSION IMPACT
11.7.1 JAPAN
11.7.1.1 INCREASING GOVERNMENT INITIATIVES FOR IMPROVING QUALITY OF VACCINES TO DRIVE MARKET
・ TABLE 251 JAPAN: VACCINES MARKET, BY TECHNOLOGY, 2021–2028 (USD BILLION)
・ TABLE 252 JAPAN: VACCINES MARKET, BY TYPE, 2021–2028 (USD BILLION)
・ TABLE 253 JAPAN: VACCINES MARKET, BY DISEASE INDICATION, 2021–2028 (USD BILLION)
・ TABLE 254 JAPAN: VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD BILLION)
・ TABLE 255 JAPAN: VACCINES MARKET, BY END USER, 2021–2028 (USD BILLION)
11.7.2 SOUTH KOREA
11.7.2.1 STRONG GOVERNMENT STRATEGIES FOR IMPROVED VACCINE HUBS TO DRIVE MARKET
・ TABLE 256 SOUTH KOREA: VACCINES MARKET, BY TECHNOLOGY, 2021–2028 (USD BILLION)
・ TABLE 257 SOUTH KOREA: VACCINES MARKET, BY TYPE, 2021–2028 (USD BILLION)
・ TABLE 258 SOUTH KOREA: VACCINES MARKET, BY DISEASE INDICATION, 2021–2028 (USD BILLION)
・ TABLE 259 SOUTH KOREA: VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD BILLION)
・ TABLE 260 SOUTH KOREA: VACCINES MARKET, BY END USER, 2021–2028 (USD BILLION)
11.7.3 CHINA
11.7.3.1 GROWING INVESTMENTS IN BIOTECHNOLOGY SECTOR TO DRIVE MARKET
・ TABLE 261 CHINA: VACCINES MARKET, BY TECHNOLOGY, 2021–2028 (USD BILLION)
・ TABLE 262 CHINA: VACCINES MARKET, BY TYPE, 2021–2028 (USD BILLION)
・ TABLE 263 CHINA: VACCINES MARKET, BY DISEASE INDICATION, 2021–2028 (USD BILLION)
・ TABLE 264 CHINA: VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD BILLION)
・ TABLE 265 CHINA: VACCINES MARKET, BY END USER, 2021–2028 (USD BILLION)
11.7.4 INDIA
11.7.4.1 INCREASING GOVERNMENT INITIATIVES AND DEVELOPMENT OF NEW AND IMPROVED VACCINES TO DRIVE MARKET
・ TABLE 266 INDIA: VACCINES MARKET, BY TECHNOLOGY, 2021–2028 (USD BILLION)
・ TABLE 267 INDIA: VACCINES MARKET, BY TYPE, 2021–2028 (USD BILLION)
・ TABLE 268 INDIA: VACCINES MARKET, BY DISEASE INDICATION, 2021–2028 (USD BILLION)
・ TABLE 269 INDIA: VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD BILLION)
・ TABLE 270 INDIA: VACCINES MARKET, BY END USER, 2021–2028 (USD BILLION)
11.7.5 REST OF ASIA PACIFIC
・ TABLE 271 REST OF ASIA PACIFIC: VACCINES MARKET, BY TECHNOLOGY, 2021–2028 (USD BILLION)
・ TABLE 272 REST OF ASIA PACIFIC: VACCINES MARKET, BY TYPE, 2021–2028 (USD BILLION)
・ TABLE 273 REST OF ASIA PACIFIC: VACCINES MARKET, BY DISEASE INDICATION, 2021–2028 (USD BILLION)
・ TABLE 274 REST OF ASIA PACIFIC: VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD BILLION)
・ TABLE 275 REST OF ASIA PACIFIC: VACCINES MARKET, BY END USER, 2021–2028 (USD BILLION)
11.8 LATIN AMERICA
・ TABLE 276 LATIN AMERICA: VACCINES MARKET, BY COUNTRY, 2021–2028 (USD BILLION)
・ TABLE 277 LATIN AMERICA: VACCINES MARKET, BY TECHNOLOGY, 2021–2028 (USD BILLION)
・ TABLE 278 LATIN AMERICA: VACCINES MARKET, BY TYPE, 2021–2028 (USD BILLION)
・ TABLE 279 LATIN AMERICA: VACCINES MARKET, BY DISEASE INDICATION, 2021–2028 (USD BILLION)
・ TABLE 280 LATIN AMERICA: VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD BILLION)
・ TABLE 281 LATIN AMERICA: VACCINES MARKET, BY END USER, 2021–2028 (USD BILLION)
11.9 LATIN AMERICA: RECESSION IMPACT
11.9.1 BRAZIL
11.9.1.1 RISING FOCUS ON IMMUNIZATION PROGRAMS BY GOVERNMENT AND NON-GOVERNMENT BODIES TO DRIVE MARKET
・ TABLE 282 BRAZIL: VACCINES MARKET, BY TECHNOLOGY, 2021–2028 (USD BILLION)
・ TABLE 283 BRAZIL: VACCINES MARKET, BY TYPE, 2021–2028 (USD BILLION)
・ TABLE 284 BRAZIL: VACCINES MARKET, BY DISEASE INDICATION, 2021–2028 (USD BILLION)
・ TABLE 285 BRAZIL: VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD BILLION)
・ TABLE 286 BRAZIL: VACCINES MARKET, BY END USER, 2021–2028 (USD BILLION)
11.9.2 MEXICO
11.9.2.1 PRESENCE OF WELL-TRAINED HEALTH PROFESSIONALS AND ETHNICALLY VARIED POPULATION BASE FOR CLINICAL TRIALS TO DRIVE MARKET
・ TABLE 287 MEXICO: VACCINES MARKET, BY TECHNOLOGY, 2021–2028 (USD BILLION)
・ TABLE 288 MEXICO: VACCINES MARKET, BY TYPE, 2021–2028 (USD BILLION)
・ TABLE 289 MEXICO: VACCINES MARKET, BY DISEASE INDICATION, 2021–2028 (USD BILLION)
・ TABLE 290 MEXICO: VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD BILLION)
・ TABLE 291 MEXICO: VACCINES MARKET, BY END USER, 2021–2028 (USD BILLION)
11.9.3 REST OF LATIN AMERICA
・ TABLE 292 REST OF LATIN AMERICA: VACCINES MARKET, BY TECHNOLOGY, 2021–2028 (USD BILLION)
・ TABLE 293 REST OF LATIN AMERICA: VACCINES MARKET, BY TYPE, 2021–2028 (USD BILLION)
・ TABLE 294 REST OF LATIN AMERICA: VACCINES MARKET, BY DISEASE INDICATION, 2021–2028 (USD BILLION)
・ TABLE 295 REST OF LATIN AMERICA: VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD BILLION)
・ TABLE 296 REST OF LATIN AMERICA: VACCINES MARKET, BY END USER, 2021–2028 (USD BILLION)
11.10 MIDDLE EAST & AFRICA
11.10.1 MIDDLE EAST
11.10.1.1 INCREASING PREVALENCE OF INFECTIOUS DISEASES TO DRIVE MARKET
・ TABLE 297 MIDDLE EAST: VACCINES MARKET, BY TECHNOLOGY, 2021–2028 (USD BILLION)
・ TABLE 298 MIDDLE EAST: VACCINES MARKET, BY TYPE, 2021–2028 (USD BILLION)
・ TABLE 299 MIDDLE EAST: VACCINES MARKET, BY DISEASE INDICATION, 2021–2028 (USD BILLION)
・ TABLE 300 MIDDLE EAST: VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD BILLION)
・ TABLE 301 MIDDLE EAST: VACCINES MARKET, BY END USER, 2021–2028 (USD BILLION)
11.10.2 AFRICA
11.10.2.1 AVAILABILITY OF FUNDS AND GRANTS FROM DEVELOPED ECONOMIES TO DRIVE MARKET
・ TABLE 302 AFRICA: VACCINES MARKET, BY TECHNOLOGY, 2021–2028 (USD BILLION)
・ TABLE 303 AFRICA: VACCINES MARKET, BY TYPE, 2021–2028 (USD BILLION)
・ TABLE 304 AFRICA: VACCINES MARKET, BY DISEASE INDICATION, 2021–2028 (USD BILLION)
・ TABLE 305 AFRICA: VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD BILLION)
・ TABLE 306 AFRICA: VACCINES MARKET, BY END USER, 2021–2028 (USD BILLION)
11.10.3 MIDDLE EAST & AFRICA: RECESSION IMPACT
12 COMPETITIVE LANDSCAPE
12.1 INTRODUCTION
12.2 KEY STRATEGIES/RIGHT TO WIN
12.3 STRATEGIES OF KEY PLAYERS IN VACCINES MARKET
・ TABLE 307 STRATEGIES ADOPTED BY MAJOR PLAYERS IN VACCINES MARKET
12.4 REVENUE SHARE ANALYSIS
・ FIGURE 34 REVENUE SHARE ANALYSIS, 2020–2022
12.5 MARKET SHARE ANALYSIS
・ FIGURE 35 MARKET SHARE ANALYSIS OF MAJOR PLAYERS IN VACCINES MARKET, 2022
・ TABLE 308 DEGREE OF COMPETITION: VACCINES MARKET
12.6 COMPANY EVALUATION MATRIX
12.6.1 STARS
12.6.2 EMERGING LEADERS
12.6.3 PERVASIVE PLAYERS
12.6.4 PARTICIPANTS
・ FIGURE 36 COMPANY EVALUATION MATRIX, 2022
12.6.5 COMPANY FOOTPRINT
12.6.5.1 PRODUCT FOOTPRINT
12.6.5.2 REGIONAL FOOTPRINT
12.7 START-UP/SME EVALUATION MATRIX
12.7.1 PROGRESSIVE COMPANIES
12.7.2 RESPONSIVE COMPANIES
12.7.3 DYNAMIC COMPANIES
12.7.4 STARTING BLOCKS
・ FIGURE 37 START-UP/SME EVALUATION MATRIX, 2022
12.7.5 COMPETITIVE BENCHMARKING
・ TABLE 309 DETAILED LIST OF KEY START-UPS/SMES
・ TABLE 310 TECHNOLOGY AND REGIONAL BENCHMARKING FOR START-UPS/SMES
12.8 COMPETITIVE SCENARIOS AND TRENDS
12.8.1 KEY PRODUCT LAUNCHES AND APPROVALS
・ TABLE 311 KEY PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021–SEPTEMBER 2023
12.8.2 KEY DEALS
・ TABLE 312 KEY DEALS, JANUARY 2021–SEPTEMBER 2023
12.8.3 OTHER KEY DEVELOPMENTS
・ TABLE 313 OTHER KEY DEVELOPMENTS, JANUARY 2021–SEPTEMBER 2023
13 COMPANY PROFILES
(BUSINESS OVERVIEW, PRODUCTS/SERVICES/SOLUTIONS OFFERED, RECENT DEVELOPMENTS, MNM VIEW)*
13.1 KEY PLAYERS 299
13.1.1 PFIZER INC.
・ TABLE 314 PFIZER INC.: COMPANY OVERVIEW
・ FIGURE 38 PFIZER INC.: COMPANY SNAPSHOT (2022)
13.1.2 MERCK & CO., INC.
・ TABLE 315 MERCK & CO., INC.: COMPANY OVERVIEW
・ FIGURE 39 MERCK & CO. INC.: COMPANY SNAPSHOT (2022)
13.1.3 GSK PLC
・ TABLE 316 GSK PLC: COMPANY OVERVIEW
・ FIGURE 40 GSK PLC: COMPANY SNAPSHOT (2022)
13.1.4 SANOFI
・ TABLE 317 SANOFI: COMPANY OVERVIEW
・ FIGURE 41 SANOFI: COMPANY SNAPSHOT (2022)
13.1.5 CSL
・ TABLE 318 CSL: COMPANY OVERVIEW
・ FIGURE 42 CSL: COMPANY SNAPSHOT (2022) 323
13.1.6 EMERGENT
・ TABLE 319 EMERGENT: COMPANY OVERVIEW 327
・ FIGURE 43 EMERGENT: COMPANY SNAPSHOT (2022)
13.1.7 JOHNSON & JOHNSON SERVICES, INC.
・ TABLE 320 JOHNSON & JOHNSON SERVICES INC.: COMPANY OVERVIEW
・ FIGURE 44 JOHNSON & JOHNSON SERVICES INC: COMPANY SNAPSHOT (2022)
13.1.8 ASTRAZENECA
・ TABLE 321 ASTRAZENECA: COMPANY OVERVIEW
・ FIGURE 45 ASTRAZENECA: COMPANY SNAPSHOT (2022)
13.1.9 SERUM INSTITUTE OF INDIA PVT., LTD.
・ TABLE 322 SERUM INSTITUTE OF INDIA PVT., LTD.: COMPANY OVERVIEW
13.1.10 BAVARIAN NORDIC
・ TABLE 323 BAVARIAN NORDIC: COMPANY OVERVIEW
・ FIGURE 46 BAVARIAN NORDIC: COMPANY SNAPSHOT (2022)
13.1.11 MITSUBISHI TANABE PHARMA CORPORATION
・ TABLE 324 MITSUBISHI TANABE PHARMA CORPORATION: COMPANY OVERVIEW
13.1.12 DAIICHI SANKYO COMPANY, LIMITED
・ TABLE 325 DAIICHI SANKYO COMPANY, LIMITED: COMPANY OVERVIEW
・ FIGURE 47 DAIICHI SANKYO COMPANY, LIMITED: COMPANY SNAPSHOT (2022)
13.1.13 PANACEA BIOTEC
・ TABLE 326 PANACEA BIOTEC: COMPANY OVERVIEW
・ FIGURE 48 PANACEA BIOTEC: COMPANY SNAPSHOT (2022)
13.1.14 BIOLOGICAL E LIMITED
・ TABLE 327 BIOLOGICAL E LIMITED: COMPANY OVERVIEW
13.1.15 BHARAT BIOTECH
・ TABLE 328 BHARAT BIOTECH: COMPANY OVERVIEW
13.1.16 NOVAVAX
・ TABLE 329 NOVAVAX: COMPANY OVERVIEW
・ FIGURE 49 NOVAVAX, INC.: COMPANY SNAPSHOT (2022)
13.1.17 INOVIO PHARMACEUTICALS
・ TABLE 330 INOVIO PHARMACEUTICALS: COMPANY OVERVIEW
・ FIGURE 50 INOVIO PHARMACEUTICALS: COMPANY SNAPSHOT (2022)
13.2 OTHER PLAYERS
13.2.1 SINOVAC
13.2.2 INCEPTA PHARMACEUTICALS LTD. 367
13.2.3 VALNEVA SE
13.2.4 VBI VACCINES INC.
13.2.5 BIO FARMA
13.2.6 FSUE NPO MICROGEN
13.2.7 ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.
13.2.8 INDIAN IMMUNOLOGICALS LIMITED
*DETAILS ON BUSINESS OVERVIEW, PRODUCTS/SERVICES/SOLUTIONS OFFERED, RECENT DEVELOPMENTS, MNM VIEW MIGHT NOT BE CAPTURED IN CASE OF UNLISTED COMPANIES.
14 APPENDIX
14.1 DISCUSSION GUIDE
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
14.3 CUSTOMIZATION OPTIONS
14.4 RELATED REPORTS
14.5 AUTHOR DETAILS